For instance, CK-positive and PD-L1-positive (CK+/PD-L1+) CTCs have been identified in various biofluids from advanced lung cancer patients and have shown significant associations with objective response rate (ORR) to PD-1/PD-L1 inhibitors.12 The gene discussed is CD274; the disease is lung carcinoma.